Cell-Free Foetal DNA as a Useful Marker for Preeclampsia Prediction

Карапетян, А. О.; Baev, Baev O.R.; Sadekova, Sadekova A.A.; Krasnyi, Krasnyi A.M.; Сухих, Г. Т.

doi:10.1007/s43032-021-00466-w

Cited by 11 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At gestational age of 8–17 weeks, the cffDNA concentration turned positive before the PE onset, with 100% sensitivity and 50% specificity [ 64 ]. This is consistent with a recent study, in which maternal blood at 11–14 weeks of pregnancy estimating a cut-off value of cffDNA concentration at 22.54 GE/ml could predict the PE with 85.0% sensitivity and 81.8% specificity [ 65 ]. Except for RASSF1A, other gene makers have been demonstrated to identify the cffDNA.…”

Section: Novel Biochemical Markers With Pe Occurrencesupporting

confidence: 92%

Diagnostic biomolecules and combination therapy for pre-eclampsia

Chen

et al. 2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Pre-eclampsia (PE), associated with placental malperfusion, is the primary reason for maternal and perinatal mortality and morbidity that can cause vascular endothelial injury and multi-organ injury. Despite considerable research efforts, no pharmaceutical has been shown to stop disease progression. If women precisely diagnosed with PE can achieve treatment at early gestation, the maternal and fetal outcomes can be maximally optimized by expectant management. Current diagnostic approaches applying maternal characteristics or biophysical markers, including blood test, urine analysis and biophysical profile, possess limitations in the precise diagnosis of PE. Biochemical factor research associated with PE development has generated ambitious diagnostic targets based on PE pathogenesis and dissecting molecular phenotypes. This review focuses on current developments in biochemical prediction of PE and the corresponding interventions to ameliorate disease progression, aiming to provide references for clinical diagnoses and treatments.

show abstract

Section: Novel Biochemical Markers With Pe Occurrencesupporting

confidence: 92%

Diagnostic biomolecules and combination therapy for pre-eclampsia

Chen

et al. 2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…The identified findings emphasize the significance of nucleic acids (especially cffDNA) in the development of PE, indicating their potential role as diagnostic markers for early detection of PE ( Sekizawa et al, 2003 ; Karapetian et al, 2021 ; Moufarrej et al, 2022 ; Zhou et al, 2023 ). Moreover, these findings suggest that endosomal TLRs activation could serve as a potential target for the treatment of PE ( Pineda et al, 2011 ; Panda et al, 2012 ; Scharfe-Nugent et al, 2012 ).…”

Section: Pathophysiology Of Preeclampsia (Pe) and Its Medical Approachmentioning

confidence: 63%

Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine’s biological mechanisms

Gajić,

Schröder-Heurich,

Mayer-Pickel

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Preeclampsia (PE) is a complex pregnancy-related disorder characterized by hypertension, followed by organ dysfunction and uteroplacental abnormalities. It remains a major cause of maternal and neonatal morbidity and mortality worldwide. Although the pathophysiology of PE has not been fully elucidated, a two-stage model has been proposed. In this model, a poorly perfused placenta releases various factors into the maternal circulation during the first stage, including pro-inflammatory cytokines, anti-angiogenic factors, and damage-associated molecular patterns into the maternal circulation. In the second stage, these factors lead to a systemic vascular dysfunction with consecutive clinical maternal and/or fetal manifestations. Despite advances in feto-maternal management, effective prophylactic and therapeutic options for PE are still lacking. Since termination of pregnancy is the only curative therapy, regardless of gestational age, new treatment/prophylactic options are urgently needed. Hydroxychloroquine (HCQ) is mainly used to treat malaria as well as certain autoimmune conditions such as systemic lupus and rheumatoid arthritis. The exact mechanism of action of HCQ is not fully understood, but several mechanisms of action have been proposed based on its pharmacological properties. Interestingly, many of them might counteract the proposed processes involved in the development of PE. Therefore, based on a literature review, we aimed to investigate the interrelated biological processes of HCQ and PE and to identify potential molecular targets in these processes.

show abstract

“…Consequently, placental dysfunction can directly affect circulating cffDNA levels. For example, in pregnancies with preeclampsia or at risk of developing preeclampsia, elevated cffDNA levels have been reported [35][36][37] . Maternal conditions, such as obesity, can lead to lower FF due to higher maternal Apoptosis is considered the primary source of cfDNA, resulting in non-random fragmentation.…”

Section: Cell-free Fetal Dnamentioning

confidence: 99%

“…In addition to levels of total cfDNA, levels of cffDNA and ctDNA in the plasma of pregnant women and cancer patients, respectively, may also differ from those of controls. By making use of Y chromosome-or placental-specific markers, studies have shown that cffDNA levels in complicated pregnancies appear to be higher [36,66] . Likewise, ctDNA level, measured by a mutation template, has been explored as a biomarker for cancer detection and treatment response [52,67] .…”

Section: Strategies To Analyze Plasma Cfdnamentioning

confidence: 99%

Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility

Che¹,

Stanley²,

Jatsenko³

et al. 2022

Extracell Vesicles Circ Nucleic Acids

View full text Add to dashboard Cite

Noninvasive sampling of an individual’s body fluids is an easy means to capture circulating cell-free DNA (cfDNA). These small fragments of DNA carry information on the contributing cell’s genome, epigenome, and nuclease content. Analysis of cfDNA for the assessment of genetic risk has already revolutionized clinical practice, and a compendium of increasingly higher-resolution approaches based on epigenetic and fragmentomic cfDNA signatures continues to expand. Profiling cfDNA has unlocked a wealth of molecular information that can be translated to the clinic. This review covers the biological characteristics of cfDNA, recent advances in liquid biopsy and the clinical utility of cfDNA.

show abstract

Cell-Free Foetal DNA as a Useful Marker for Preeclampsia Prediction

Cited by 11 publications

References 23 publications

Diagnostic biomolecules and combination therapy for pre-eclampsia

Diagnostic biomolecules and combination therapy for pre-eclampsia

Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine’s biological mechanisms

Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility

Contact Info

Product

Resources

About